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Human Immunodeﬁciency virus type 1 (HIV-1) disproportionately affects women, accounting for 450%
of new HIV infections in adults worldwide. While multiple mechanisms may contribute to a greater
degree of HIV infection in women than men, we evaluated the direct effect of 17β-estradiol, the most
bioactive form of estrogen in women, on HIV replication in peripheral blood mononuclear cells (PBMCs).
We demonstrate that 17β-estradiol, in an ERα dependent manner, inhibits HIV replication by activating β-
catenin signaling. Speciﬁcally, we show for the ﬁrst time that 17β-estradiol induces a complex formation
between ERα and β-catenin which tether on the HIV LTR at −143 nt site from +1 start site of HIV
transcription to repress HIV promoter activity. These studies deﬁne a role of 17β-estradiol in inhibiting
HIV replication which may impact HIV pathogenesis in women and add to a growing list of viruses that
are inhibited by 17β-estradiol through ERα engagment.
& 2013 Elsevier Inc. All rights reserved.Background
The current HIV pandemic is heavily skewed against women. HIV
infection in women accounts for 450% of new HIV infections in
adults worldwide. Once infected, emerging data points to differences
in HIV pathogenesis and anti-HIV immune responses in women in
comparison to men (Gandhi et al., 2002; Meier et al., 2009; Sterling
et al., 2005; Weinberg et al., 2011). Female sex hormones, at least in
part, may contribute to gender-based differences in HIV acquisition
and pathogenesis. Particularly, female sex hormones regulate
immune responses both systemically and in the female genital tract
by impacting homing of HIV-susceptible cells to mucosal tissue,
regulating cytokine production and antimicrobial peptides induction,
and inﬂuencing lymphocyte responses (Fahey et al., 1999; Fahey and
Wira, 2002; Fung et al., 2013; Kaushic et al., 1998; Lu et al., 2002;
Quayle et al., 1998; Rodriguez-Garcia et al., 2013). This intricate
balance between host factors under female sex hormone regulation
and HIV is likely to impact HIV transmission and pathogenesis
in women.
Some clinical data suggest that lower estrogen level (e.g. proges-
terone dominant stage) is correlated with higher rate of HIV infectionll rights reserved.
arthi).and higher plasma viral load. Speciﬁcally, during the periovulatroy
stage of the menstrual cycle, when estrogen dominates, HIV plasma
viral load is decreased (Greenblatt et al., 2000; Hanna, 1999; Money
et al., 2003). Further, HIV productive infection of human cervical
explant tissue predominately occurs in tissue obtained from women
in their secretory phase of the menstrual cycle, a stage where
progesterone dominates and counteracts estrogen effects (Saba
et al., In press). Lastly, women on progesterone-based injectable
hormonal contraceptives are more likely to become HIV infected and
to transmit the virus to their male partners (Heffron et al., 2012).
Taken together, these clinical observations suggest that estrogen
dominance may be linked to lower susceptibility of cells to HIV
infection.
17β-Estradiol, the most potent estrogen found in humans, exerts
an anti-viral effect for a number of viruses. It inhibits hepatitis C virus
(HCV) infection at multiple steps including attachment, entry,
replication, and post-replication (Hayashida et al., 2010; Murakami
et al., 2013). It also inhibits hepatitis B virus (HBV) transcription
(Wang et al., 2012), limits herpes simplex virus (HSV) primary
infection and reactivation (Gillgrass et al., 2010; Vicetti Miguel
et al., 2010), and inhibits rubella virus replication (Roehrig et al.,
1979). 17β-Estradiol, on the other hand, promotes the replication of
adenovirus type 12 (James et al., 1992).
The signal transduction cascade of estrogen is complex and can be
engaged by multiple pathways. Canonical estrogen signaling involves
E.L. Szotek et al. / Virology 443 (2013) 375–383376the activation of its nuclear receptors, estrogen receptor α (ERα) or
estrogen receptor β (ERβ), which in turn bind to estrogen responsive
elements (ERE) located near or within gene promoters to regulate the
transcriptional activity of cognate target genes (Marino et al., 2006).
Estrogen also regulates gene expression via noncanonical signaling
whereby (Marino et al., 2006) estrogen receptors bind to other
transcriptional factors such as Sp1 or Ap-1, leading to either their
stabilization of recruitment of transcriptional co-regulators, which in
turn bind to their cognate promoters to regulate gene expression.
Also, estrogen can bind to either its nuclear receptors or other
receptors to initiate second messenger signaling leading to physio-
logic effects. These signal transduction pathways include ERK/MAPK,
p38/MAPK, or PI3K/AKT, to name a few (Marino et al., 2006).
Interestingly, many of the reported 17β-estradiol reported anti-viral
effects are mediated by ERα and not ERβ (Hayashida et al., 2010;
Murakami et al., 2013; Wang et al., 2012; Gillgrass et al., 2010; Vicetti
Miguel et al., 2010; Roehrig et al., 1979).
β-Catenin signaling represses HIV replication in multiple tar-
gets, including PBMCs at the level of transcription (Henderson
et al., 2012; Kumar et al., 2008; Li et al., 2011). β-Catenin is a
transcriptional co-regulator and is the central mediator of the
canonical Wnt/β-catenin signaling pathway (Al-Harthi, 2012).
β-catenin binds to members of the TCF/LEF family of transcription
factors (TCF1, TCF3, TCF-4, and LEF) to modulate hundreds of
genes, including those that regulate cell proliferation and survival.
β-catenin expression is regulated at the protein level by a multi-
protein destruction complex (GSK-3β, APC, Axin, and casein kinase
1). This multi-protein complex leads to the phosphorylation,
ubiquitination, and proteasomal degradation of β-catenin. When
this destruction complex is destabilized, β-catenin is hypopho-
sphorylated and translocates to the nucleus where it binds to TCF/
LEF transcription factors, tethering on their cognate DNA binding
sites to regulate genes such as CyclinD, C-Myc, Matrix metallopro-
teinase 7 and 9, and Axin, to name a few (Al-Harthi, 2012).
At least four TCF-4 binding sites have been identiﬁed within the
HIV promoter at −143 to −136 nt; −336 to −329 nt; +66 to +73 nt;
and +186 to +195 nt from the transcription initiation site (Henderson
et al., 2012). While all sites have 470% homology to the TCF-4
binding sequence, the −143 site has 100% homology to the TCF-4 core
(5′-(A/T)(A/T)CAAAG-3′) and is present in approximately one-third of
500 HIV LTR sequences reported in the Los Alamos gene bank
(Henderson et al., 2012). TCF-4 binds at a higher afﬁnity at −143
than at any other site (Henderson et al., 2012). Further, β-catenin is
tethered on the HIV LTR at the nt−143 site and knockdown of either
TCF-4 or β-catenin enhances HIV transcription (Henderson et al.,
2012; Narasipura et al., 2012). Dual knock down of β-catenin and
TCF4 does not further enhance HIV LTR activity, indicating that these
factors work together to repress HIV transcription.
Given that HIV replication is regulated by a complex interplay
between virus and host factors and some epidemiologic data
linking an estrogen dominant state to lower plasma viral load
and infection rate, we directly assessed the role of estrogen (17β-
estradiol) on HIV replication in peripheral blood mononuclear cells
(PBMCs). We demonstrate that estrogen through engaging ERα
leads to association between ERα and β-catenin that tethers on the
HIV LTR at −143 nt from the transcription initiation site to repress
HIV transcription. These ﬁndings provide the ﬁrst direct associa-
tion between ERα and β-catenin on the HIV LTR, impacting HIV
transcription. Further, the mechanism revealed here may contri-
bute to some clinical observations linking lower HIV load under an
estrogen dominant state (Asin et al., 2008; Greenblatt et al., 2000;
Money et al., 2003). Most importantly, these studies add to a
growing list of viruses (HCV, HBV,HSV, rubella) that are inhibited
by ER through ERα engagment (Gillgrass et al., 2010; Hayashida
et al., 2010; Murakami et al., 2013; Roehrig et al., 1979; Vicetti
Miguel et al., 2010; Wang et al., 2012).Results
17β-Estradiol inhibits HIV replication in PBMCs
PBMCs were stimulated with anti-CD3/CD28 prior to HIVBal
infection then treated with 17β-estradiol (0–3 nM) or AZT (1 μM).
At day seven post infection, HIV replication was monitored by
conventional HIV core antigen (p24) ELISA. We demonstrate that
17β-estradiol at 1.5 and 3 nM inhibited HIV replication by approxi-
mately 40% (Fig. 1a). 17β-Estradiol at these two doses also inhibited
HIV strain (IIIB), a T-tropic/CXCR-4 utilizing strain (Fig. 1b). None of
these 17β-estradiol doses (0.001–3 nM) were cytotoxic to PBMCs, as
evaluated by the MTS assay (data not shown).
Robust expression of ER α in PBMCs
To determine which estrogen receptor (ERα or ERβ) is involved in
17β-estradiol-mediated inhibition of HIV replication, we evaluated
ERα and ERβ expression in PBMCs. Using an antibody that recognizes
both ERα and ERβ we show that ER expression is 480% in all
lymphocyte subsets and that T cell activation through anti-CD3/CD28
stimulation did not signiﬁcantly increase ER expression in T cells
(Fig. 2a and b). Using an antibody that is speciﬁc for either ERα or ERβ,
we demonstrate robust expression of ERα in PBMCs and low level of
ERβ expression (Fig. 2c). 17β-Estradiol treatment of PBMCs at doses
that inhibited HIV replication (1.5 and 3 nM) did not signiﬁcantly
induce ERα or ERβ expression (Fig. 2c).
17β-Estradiol inhibition of HIV replication is dependent on ERα and is
at the level of HIV transcription
To determine the role of ERα or ERβ in estrogen mediated
inhibition of HIV, we used an ERα agonist and an ERβ antagonist.
We were unable to use an ERα antagonists in PBMCs because ERα
antagonists are highly context dependent and in some cases they
function as agonist instead of antagonist. For example, 1,3-bis(4-
hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-
pyrazole dihydrochloride (known as MPP) depending on the cell
type can be an ERα agonist or antagonist (Shang and Brown, 2002).
In PBMCs, ER agonists functioned as antagonist (data not shown).
For this reason, we used an ERα agonist (4,4′,4″-(4-Propyl-[1H]-
pyrazole-1,3,5-triyl)trisphenol, PPT) to assess if engaging ERα leads
to HIV inhibition. PPT inhibited HIV replication by approximately
40%, a magnitude that was similar to that mediated by 17β-
estradiol (Fig. 3a). The ERβ antagonist (2-Phenyl-5,7-bis(triﬂuor-
omethyl) pyrazolo[1,5-a]pyrimidin-3-yl]phenol, PHTPP) did not
abrogate the ability of 17β-estradiol to inhibit HIV replication in
PBMCs (Fig. 3b). Together, these ﬁndings indicate that the mechan-
ism by which 17β-estradiol mediates HIV inhibition is dependent
on ERα and is independent of ERβ. To determine the step of the
HIV life cycle whereby 17β-estradiol may exert its inhibitory effect,
PBMCs were infected with HIVBal and HIV reverse transcription,
integration, and transcription were assessed by conventional real
time PCR-based assays. 17β-estradiol inhibited HIV transcription
by approximately 40% and had no effect on HIV reverse transcrip-
tion or integration (Fig. 4c–e).
17β-Estradiol induces β-catenin signaling
Given that 17β-estradiol inhibited HIV transcription and we
deﬁned β-catenin through its interaction with TCF-4 as a potent
repressor of HIV transcription (Henderson et al., 2012; Kumar et al.,
2008; Narasipura et al., 2012), we evaluated the relationship between
17β-estradiol and β-catenin signaling. 17β-Estradiol induced active
β-catenin expression in PBMCs as evaluated by Western blot (Fig. 5a)
and intracellular staining for β-catenin (Fig. 5b). 17β-estradiol also
Fig. 2. PBMCs predominately express ERα. PBMCs were stimulated with anti-CD3/
CD28 antibodies for 48 h, left untreated in (a) and (b) or treated with 1.5 nM or
3 nM 17β-estradiol in (c). Expression of estrogen receptors (ER) was determined by
intracellular ﬂow cytometry (a,b) or by Western blot (c). A representative
histogram of expression of 17β-estradiol receptors (ERα and ERβ) in PBMCs is
shown in (a) and ER expression in leukocyte subsets is shown in (b). Expression of
ERα and ERβ detected by Western blot in PBMCs is shown in (c). Data is
representative of a minimum of four donors. Error bars represent standard
deviation of the mean.
Fig. 1. 17β-Estradiol inhibits HIV replication in PBMCs. PBMCs were stimulated
with anti-CD3/CD28 antibodies for 48 h, infected with HIVBal (a) or IIIB (b), re-
suspended in phenol red free-RPMI complete medium, and treated with 17β-
estradiol (0–3 nM), 1 μM AZT, or left untreated. Seven day post-infection, HIV p24
level was measured by conventional ELISA from HIVBal (a) or HIV IIIB (b) infected
cells. Data is representative of median value from a minimum of four donors,
performed in quadruplicates. The bars represent the data range, where the 25th,
50th and 75% median percentile values are shown and analyzed using Mann–
Whitney test. npo0.05; nnpo0.01.
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such as axin-2, c-Myc, and cyclinD1 (Fig. 5c). Inhibition of TCF-4
through transfection with a dominant negative TCF-4 construct
abrogated the ability of 17β-estradiol to induce axin-2 mRNA,
indicating that 17β-estradiol-mediated induction of axin-2 is
β-catenin speciﬁc (Fig. 5d). Collectively, these data demonstrate that
17β-estradiol activates β-catenin signaling. This is the ﬁrst study, toour knowledge, to demonstrate 17β-estradiol activation of β-catenin
signaling in PBMCs.
17β-Estradiol induces the stable association of β-catenin and ERα
We assessed the interaction between ERα and β-catenin in
PBMCs by immunoprecipitation (IP) and western blot (WB). While
β-catenin was pulled down by ERα IP, the level of β-catenin pulled
down by ERα IP was signiﬁcantly higher when the cells were
treated with 17β-estradiol (Fig. 6a). These data indicate that 17β-
estradiol potentiates the interaction between ERα and β-catenin,
which maybe driven by higher level of β-catenin in response to
17β-estradiol or stabilization of β-catenin in presence of 17β-
estradiol to promote its interaction with ERα.
Inhibiting β-catenin abrogates the ability of 17β-estradiol to inhibit
HIV replication
XAV and IWR-1 Endo are two small molecules described to
inhibit β-catenin signaling by stabilizing axin-2, a scaffolding
protein that is part of the β-catenin destruction complex (Huang
Fig. 3. 17β-estradiol engages ERα and not ERβ to repress HIV replication. PBMCs were stimulated with anti-CD3/CD28 antibodies, infected with HIVBal, and treated with 17β-
estradiol (1.5 nM) with or without an ERα agonist (PPT) at 1 mM (a) or an ERβ antagonist (PHTPP) at 100 nM (b). HIV p24 ELISA was performed at day seven post infection.
Data is representative of a minimum of four donors, performed in quadruplicate. Data was analyzed by Student T-test; npo0.05.
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ubiquitinated, and tagged for proteasomal degradation. Treating
HIV infected PBMCs in the presence of 17β-estradiol and XAV or
IWR-1endo abrogated 17β-estradiol inhibition of HIV replication
(Fig. 6b). Collectively, these data indicate that the mechanism by
which 17β-estradiol mediates HIV inhibition is both ERα depen-
dent and β-catenin dependent.
ERα, β-catenin, and TCF-4 associate with the HIV LTR at −143 nt site
from transcription initiation site
We evaluated whether ERα, β-catenin, and TCF-4 are associated
with the HIV LTR to repress transcription. β-catenin does not bind DNA
directly rather acts as a transcription co-factor by binding to TCF/LEF
transcription factors. Recently several TCF-4 binding sites were identi-
ﬁed on the HIV LTR (Henderson et al., 2012). One in particular, at −143
from +1 transcription start site (−143 to −136 nt) is where TCF-4 and
β-catenin associate with the nuclear matrix protein SMAR1 to pull the
HIV DNA towards the nuclear matrix and away from RNA pol II
transcriptional machinery (Henderson et al., 2012). We assessed
whether ERα tethers at −143 by chromatin immunoprecipitation.
Jurkat cells were transfected with ERα plasmid and WT-LTR or an
LTR deleted in −143 from the +1 start site (LTR Δ −143). The chromatin
was pulled down using IgG or ERα antibody and the DNA ampliﬁed for
HIV LTR. We show that deletion of −143 dramatically diminished the
association of ERα with the HIV LTR at the −143 site (Fig. 7a). Further,
β-catenin and TCF-4 were conﬁrmed to associate with
the HIV LTR at −143 (Fig. 7b). Collectively, these data demonstrate
that ERα, β-catenin, and TCF-4 all associate at −143 nt site of the
HIV LTR.Discussion
17β-Estradiol levels greatly ﬂuctuate during the menstrual cycle,
reaching peak levels in the preovulatory phase (4690 to
o2,120 pmol/l) and declining in the luteal phase (4300 to o710pmol/l) (Harlow and Ephross, 1995). The level of 17β-estradiol is also
highly variable among women and within the samewoman from one
menstrual cycle to the next. For this reason, we evaluated a wide dose
of 17β-estradiol effects on HIV replication in PBMCs. We show here
that 17β-estradiol at a physiologic dose reported during the preovu-
latory phase of women of reproductive age (1.5 nM equivalent to
1500 pmol/l) (Harlow and Ephross, 1995) inhibits HIV replication in
PBMCs at the level of transcription by engaging the association
between β-catenin, TCF-4 and ERα at −143 nt site of the HIV LTR.
The −143 nt site of the HIV LTR is of a particular importance because
it was recently demonstrated to be associated with β-catenin/TCF-4/
and SMAR protein to inhibit POLII docking and repress HIV transcrip-
tion (Henderson et al., 2012). Based on our data we propose that
under low level of 17β-estradiol minimal interaction between ERα
and β-catenin occurs, which does not protect β-catenin from degra-
dation. However, under a 17β-estradiol dominant state, the interac-
tion between ERα and β-catenin is induced leading to stabilization of
β-catenin, its subsequent translocation into the nucleus, and its
association with TCF-4 to repress HIV LTR activity. Although the LTR
has estrogen responsive elements (EREs) at 343 and −231 nt from
transcription initiation site, those sites are not relevant to the
association between β-catenin and ERα on the HIV LTR, as deletion
of −143 nt site alone abrogated the tethering of β-catenin, TCF-4, and
ERα on the HIV LTR.
Our ﬁndings suggest that ﬂuctuations in 17β-estradiol levels
during the menstrual cycle and across the reproductive stage of
women may impact HIV load and in turn HIV pathogenesis and
transmission. Indeed, some studies reported that HIV genital shed-
ding is highest during menses (low estrogen) and declines during the
follicular stage (high estrogen). Other studies found that the men-
strual cycle leads to a decline in plasma HIV load in the follicular to
mid-luteal stage (high estrogen) without impacting HIV vaginal
shedding (Greenblatt et al., 2000; Hanna, 1999; Reichelderfer et al.,
2000, 2002; Villanueva et al., 2002). Mid-secretory levels of estrogen
and progesterone, together, were also found to inhibit HIV replication
in vitro in PBMCs (Asin et al., 2008). However, depending on the
estrogen dose, there was either no effect or negligible effect on HIV
Fig. 4. 17β-estradiol inhibits HIV transcription: PBMCs were stimulated with anti-CD3/CD28 antibodies, infected with HIVBal and treated with 17β-estradiol (1.5 nM or 3 nM)
or left untreated. Genomic DNAwas isolated at day one post infection to measure HIV reverse transcription by PCR (a). Genomic DNAwas isolated at day three post infection
to measure HIV integration by Alu PCR (b). Cellular RNAwas isolated at day three post infection to measure HIV transcripts by RT-PCR (c). Data in (a)–(c) is representative of a
minimum of three experiments. Data was analyzed by Student T-test; npo0.05; nnpo0.01.
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several experimental factors, the most important of which is the use
of charcoal stripping in these studies. In our study, the ability of 17β-
estradiol to inhibit HIV replication in PBMCs was conducted without
charcoal stripping. Historically, charcoal stripping of FBS was per-
formed to remove endogenous steroid hormones, especially in breast
and cervical cancer cell lines that are highly enriched in steroid
production. However, emerging evidence indicates that charcoal
stripping eliminates other metabolites essential for cellular health
(Cao et al., 2009). In our experience, charcoal stripping of FBS
compromises the survival of PBMCs (data not shown). For this reason
and because untreated cultures serve as background for endogenous
17β-estradiol/steroids levels, we have elected not to use charcoal
stripping in our cultures and showed that 17β-estradiol at preovula-
troy doses inhibits HIV replication and revealed the mechanism by
which it does so.
Cross-talk between 17β-estradiol and Wnt/β-catenin has been
described in mouse and human epithelial cells (Hou et al., 2004
Kouzmenko et al., 2004). We provide the ﬁrst evidence in human
PBMCs that 17β-estradiol induce ERα and β-catenin interaction to
potentiate HIV repression. In human and mouse uterine epithelial
cells, 17β-estradiol induces β-catenin gene expression and activates a
number ofWnt proteins, includingWnt4, Wnt5a, and frizzled receptor
2 (Hou et al., 2004). Further, ERα and β-catenin in human colon and
breast cancer cells precipitate within the same immune complexes
(Kouzmenko et al., 2004), demonstrating that ERα and β-catenin are
physically associated with each other. Exogenous 17β-estradiol furtherenhances this physical interaction of ERα and β-catenin. The result of
ERα and β-catenin physical association is a reciprocal regulation of
cognate target genes (Kouzmenko et al., 2004).
ERα represses the replication of a number of viruses, including
HCV, HBV, HSV, and rubella (Gillgrass et al., 2010; Hayashida et al.,
2010; Murakami et al., 2013; Roehrig et al., 1979; Vicetti Miguel et al.,
2010; Wang et al., 2012). We show here that ERα also inhibits HIV
replication. These ﬁndings indicate that ERα engages direct anti-viral
pathways to limit replication of some viruses, which may mediate
gender-speciﬁc differences in susceptibility to virus infection and/or
spread. In the case of HCV, women are more likely to clear HCV in
acute stage than men and female sex hormones have been suggested
as a potential factor for better clearance (Bakr et al., 2006). Some
studies have also alluded to women having a 2–6 fold lower plasma
viral load than men during acute and chronic HIV infection (Delmas
et al., 1997; Gandhi et al., 2002; Lemly et al., 2009; Meditz et al., 2011;
Sterling et al., 1999, 2001), although additional studies are needed to
assess the direct contribution of female sex hormones on HIV
replication and progression in the clinical setting suggest.Materials and methods
Ethics statement
This study was approved by Rush Institutional Review Board
(09040706-IRB01) and participants’ written consent was provided.
Fig. 5. 17β-estradiol induces β-catenin signaling. PBMCs were stimulated and treated with 17β-estradiol (1.5 nM) for three days. Western blot and densitometry
quantiﬁcation for active β-catenin measured by Western blot is shown in (a). Flow cytometric analysis of active β-catenin expression in CD4+ and CD8+ T cells is shown in
(b). Level of downstream targets of Wnt/β-catenin pathway (axin-2, c-Myc, cyclin D-1) post 17β estradiol treatment performed by real time RT-PCR is shown in (c). GAPDH
was used as endogenous control and data shown as fold change relative to untreated cells. In (d) PBMCs were stimulated with antiCD3/CD28 for 48 h and nucleofected with a
dominant negative plasmid for TCF-4 (dnTCF4) or backbone vector (pcDNA). Post nucleofection the cells were treated with 17β-estradiol (1.5 nM) for three days and axin-2
and c-myc mRNA level was evaluated by real-time RT-PCR. GAPDH was used as endogenous control. Data is representative of a minimum of three experiments and analyzed
by Student T-test; npo0.05.
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AZT, 17β-estradiol, PHTPP (4-[2-phenyl-5,7-bis(triﬂuoromethyl)
pyrazolo[1,5-a]pyrimidin-3-yl]phenol), PPT (4,4′,4′′-(4-propyl-[1H]-
pyrazole-1,3,5-triyl) trisphenol), anti-total β-catenin antibody, amino
acids 768-781 (cat. C2206), and anti-GAPDH antibody (cat. G9545)
purchased from Sigma Aldrich (St. Louis, MO, USA). Anti-active β-
catenin antibody clone 3C196 purchased from US Biologicals (San
Antonio, TX, USA). Anti-ERα antibody clone 62A3 purchased from
Cell Signaling (Boston, MA). Anti-ERβ antibody clone 14C8 purchased
from Abcam (Cambridge, MA, USA). XAV 939 and IWR-1-endo
purchased from Tocris Bioscience (Bristol, United Kingdom).Isolation and treatment of PBMCs
PBMCs were isolated from venous blood of healthy women
of reproductive age and not on hormone contraceptives using
lymphocyte separation medium (Lonza Biotech, Allendale,
NJ, USA) and density centrifugation. The cells were suspended
in phenol red free-RPMI complete medium supplemented with
10% fetal bovine serum (FBS), 1% L-glutamine, 1% penicillin,
1% streptomycin, and 20 U/ml IL-2. PBMCs were left unstimulated
or stimulated with 1 μg/ml each of anti-CD3/CD28 antibodies
(BD Biosciences, Franklin Lake, NJ, USA) for 24 h at 37 1C under
5% CO2.
E.L. Szotek et al. / Virology 443 (2013) 375–383 381Immunoﬂuorescence staining and ﬂow cytometric analysis
Up to nine-color ﬂow cytometric analyses were performed
using a FACSCalibur cytometer with CellQuest (BD) and LSR-IIFig. 6. 17β-estradiol-mediated inhibition of HIV replication is β-catenin-dependent
PBMCs were stimulated with anti-CD3/CD28 antibodies for 48 h then left untreated
or treated with 17β-estradiol (1.5 nM). At day three, the cells were harvested, lysed,
and the protein immunoprecipitated (IP) using ERα antibodies or IgG control then
probed with β-catenin (a). In (b) the ability of small molecule inhibitors of β-catenin
to abrogate 17β-estradiol-mediated inhibition of HIV replication is shown. Speci-
ﬁcally, PBMCs were stimulated with anti-CD3/CD28, infected with HIVBal, left
untreated or treated with 17β-estradiol at 1.5 nM with or without small molecule
inhibitors of β-catenin (XAV at 1 mM and IWR-1-endo at 2.5 mM) or treated with
1 μM AZT. HIV p24 was measured by ELISA on day seven post-infection. HIV p24
levels form XAV and IWR-1-endo treatments alone, without 17β-estradiol, was not
statistically different than untreated cultures. Data is representative of a minimum
of three experiments and analyzed by Student T-test; npo0.05, NS indicate not
signiﬁcant (p40.05).
Fig. 7. Tethering of ERα, β-catenin, and TCF-4 at -143 site on the HIV LTR. Jurkat cells we
from −143 to −136 nt from +1 site) with or without ERα plasmid. ChIP was performed w
DNA ampliﬁed for HIV LTR. Data represent fold change in comparison to IgG of at lea
determined by Student T-test.cytometer with Diva software (BD). Aqua Live/Dead staining was
used. The following antibodies from BD Biosciences were used for
cell surface staining as per instructions: For T cells subsets, CD3-
alexaﬂuor 700, CD14-paciﬁc blue, CD8-phycoerythrin-cyanine
(PerCP-Cy) 5.5, CD4-allophycocyanin (APC), CD19 APC-H7; for
dendritic cell subsets, CD3-PerCP-Cy7, CD123-phycoerythrin (PE),
HLA-Dr PerCP, CD14-paciﬁc blue, CD11c-APC, CD56/CD16-alexﬂuor
700 and CD19/CD20-APC-H7. Proper isotypes were purchased
from same vendor for primary stain. Intracellular ﬂow cytometry
staining was performed using CytoPerm/ﬁx and CytoWash
reagents, according to recommendations of the supplier (BD
Biosciences). For ERs staining, 10 μl of a FITC-conjugated rabbit
monoclonal antibody that recognizes both ERα and ERβ (clone SP1,
Abcam, Cambridge, MA, USA) was used. For active β-catenin,
200 μl of 0.05 μg dilution in PBS of mouse anti-human active
β-catenin un-conjugated antibody (clone 3C196, US Biological,
Marbelhead, MA) was used followed by 1 μl of a secondary anti-
mouse F(ab′)2 FITC-conjugated antibody at 2 mg/ml. The cells
were subsequently washed and ﬁxed with 2% paraformaldahyde.
Cell viability, HIV infection, and p24 assay
Cell viability was assessed by standard MTS assay (Promega,
Madison, WI). HIV-1Bal or HIVIIIB at 2 ng HIV p24/106 cells was added
to anti-CD3/CD28 stimulated PBMCs and incubated for 4–6 h at 37 1C
under 5% CO2. Cells were then washed with PBS three times to
remove un-bound virus, suspended in phenol red free-RPMI complete
medium with 20 units/ml IL-2, treated as indicated per experimental
condition, and plated in 96 well U-bottom plate at 200,000 cells/
200 μl volume of the media in quadruplicates for 7 days at 37 1C, 5%
CO2. HIV p24 assay was performed using p24 ELISA kit (SAIC-
Frederick, MD) according to the manufacturer's protocol.
Western blot and immunoprecipitation (IP)
The cells were lysed using RIPA buffer (Sigma) with 10%
protease inhibitors and protein content measured by Pierce BCA
assay (Thermo Fisher, Barrington, IL). Western blot was performed
as described (Narasipura et al., 2012), using anti-active β-catenin
antibody at 1:8000, anti-total β-catenin antibody at 1:8000, anti-
ERα at 1:1000, anti ERβ at 1:1000, and/or anti-GAPDH at 1:30,000.
Secondary antibodies included goat anti-mouse HRP (Pierce) at
1:50,000 and goat anti-rabbit HRP (Cell Signaling) at 1:60,000 for
GAPDH. Densitometries were measured by ImageJ software. For IP,
cell lysate was pre-cleared with 25 μl of protein A/G magneticre transfected with wild-type (WT) LTR or LTR deleted in -143 (LTR Δ −143, deletion
ith either pull down with ERα antibody (a) or β-catenin or TCF-4 antibodies (b) and
st two independent experiments. Asterisks denote po0.05 in comparison to IgG
E.L. Szotek et al. / Virology 443 (2013) 375–383382beads (Thermo Scientiﬁc), cross-linked with speciﬁc antibodies
using Protein A/G MagSepharose and SpinTrap Buffer Kit (GE
Healthcare, Piscataway, NJ) as outlined by manufacturer. Dena-
tured proteins were then resolved on a 12% SDS gel. IgG controls
were run in parallel.
RNA isolation and real time PCR
Total RNA was isolated from PBMCs using Trizol (Life Technol-
ogies, Grand Island, NY). Complimentary DNA synthesis was per-
formed using qScript cDNA Supermix (Quanta BioSciences,
Gaithersburg, MD). Real-time PCR was performed employing Sso-
Fast EvaGreen Supermix with low ROX (BioRad, Hercules, CA) in a
7500 real time PCR system (Applied Biosystems, Carlsbad, CA) to
quantify target genes. Reaction conditions were: 95 1C for 10 min
followed by 40 cycles of 95 1C for 15 s, 60 1C for 1 min and 95 1C for
30 s. A melting curve stage was included to make sure that single
speciﬁc products were ampliﬁed devoid of non-speciﬁc products or
primer-dimers. Fold change in product expression was calculated by
relative quantiﬁcation using the comparative CT method with
GAPDH as endogenous control. The following primers were used
to amplify Wnt/β-catenin pathway target genes: c-Myc, F- 5′-ACGTC
TCCACACATCAGCACAACT and R-5′-TGACACTGTCCAACTTGACCCTCT;
CyclinD1, F-5′-TCATGGCTGAAGTCACCTGGT and R-5′-TCCACTGGA-
TGGTTTGTCACTGGA; Axin2, F-5′-ACAACAGCATTGTCTCCAAGCAGC
and R-5′-GCGCCTGGTCAAACATGATGGAAT and GAPDH, F-5′-TGA-
CTTCAACAGCGACACCCACT and R-5′-ACCACCCTGTTGCTGTAGCC
AAAT.
Analysis of HIV reverse transcription, integration and transcription
Stimulated PBMCs were infected with HIVBal and treated or
untreated as described above. For HIV reverse transcription
analysis, infected cells were harvested at 24 h, genomic DNA
isolated using DNeasy blood and tissue kit (Qiagen, Valencia,
CA), quantitative real time PCR was performed to quantify HIV
LTR using F-5′-TCAAGTGAGTGCCCGGTT and R-5′-AGCTCCGGTTTCT
CTTTCGCT primers. For HIV integration analysis, infected cells
were harvested at 72 h AND Alu-PCR was performed as described
(Brussel and Sonigo, 2003). A minus Taq and a minus template
controls were included throughout. For HIV transcription analysis,
at 72 h post infection, cDNA was subjected to real time PCR using
the following primers to amplify HIV transcripts: Rev, F-5′-TCCT
TGGCACTTATCTGGGACGAT and R-5′-TCCCAGAAGTTCCACAATCC-
TCGT and Env, F-5′-ACGAGGATTGTGGAACTTCTGGGA and R-5′–
TGGCATTGAGCAAGCTAACAGCAC. GADPH was used as endogenous
control.
Nucleofection and transfection
Stimulated PBMCs were transfected with dominant negative
(dn) TCF-4 plasmid (Addgene; Cambridge, MA) and pcDNA back-
bone (Invitrogen; Carlsbad, CA) using Amaxa T cell Nucleofection
kit and Amaxa Program T-23 (Lonza, Walkersville, MA). Jurkat cells
were transfected with 0.5 μg ERα expression plasmid (pEGFP-C1-
ER alpha, Addgene, Cambridge, MA), 0.5 μg of either the WT-LTR or
Δ-143-LTR previously described (Henderson et al., 2012) using
Lipofectamine 2000 (Invitrogen).
Chromatin immunoprecipitation (ChIP) and quantitative real-time
PCR
At 48 h post-transfection, chromatin immunoprecipitation (ChIP)
was performed using EMD Millipore EZ Magna ChIPA/G (Temecula,
CA) according to manufacturer's protocol with antibodies for total β-
catenin (Sigma) and ERα (Thermo). An appropriate IgG (CellSignaling)control antibody was also included. Real time PCR was performed to
quantify HIV LTR DNA using above mentioned LTR primers in a 7500
real time PCR system employing SsoFast EvaGreen Supermix with low
ROX. Reaction conditions were: 95 1C for 10 min followed by 40 cycles
of 95 1C for 15 s, 60 1C for 1 min and 95 1C for 30 s. A melting curve
stage was included to ensure ampliﬁcation of a single product. Change
in binding was calculated by relative quantiﬁcation using the com-
parative threshold cycle (CT) method. Results were reported as fold
change relative to IgG control (ΔCT¼CT Target−CT IgG control; fold change
relative to IgG control¼2−ΔCt).
Statistics
When the data was distributed normally, ANOVA and post-hoc
tests were used. When the data was not normally distributed,
nonparametric analysis was performed. All tests assumed a two-
sided signiﬁcance level of 0.05. GraphPad Instat 3 software (San
Diego, CA) was used for data analysis.Funding
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